Advertisement
Advertisement
STVN
Stevanato Group S.p.A.
15.65
USDSponsored
-0.28
-1.76%
Nov 20, 15:59 UTC -5
Closed
After-Market
15.68
+0.03
+0.19%
Stevanato Group S.p.A. (STVN) Earnings
STVN Earnings Reports
Positive Surprise Ratio
STVN beat 15 of 22 last estimates.
68%
Next Report
Date of Next Report
Mar 02, 2027
Estimate for Q4 26 (Revenue/ EPS)
$381.34M
/$0.20
Implied change from Q3 26 (Revenue/ EPS)
+16.94%
/+25.00%
Implied change from Q4 25 (Revenue/ EPS)
+10.06%
/+11.11%
Stevanato Group S.p.A. earnings per share and revenue
On Nov 03, 2026, STVN reported earnings of 0.16 USD per share (EPS) for Q3 26, beating the estimate of 0.15 USD, resulting in a 0.76% surprise. Revenue reached 326.10 million, compared to an expected 327.35 million, with a -0.38% difference. The market reacted with a -28.57% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 0.20 USD, with revenue projected to reach 381.34 million USD, implying an increase of 25.00% EPS, and increase of 16.94% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Apnimed, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.62
Actual
-$0.99
Surprise
-59.11%

Larimar Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.35
Actual
-$0.28
Surprise
+17.38%

Lexeo Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.33
Actual
-$0.43
Surprise
-28.17%

Galectin Therapeutics Inc.
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.05
Actual
-$0.04
Surprise
+21.57%

NRX Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.21
Actual
-$0.05
Surprise
+76.94%

Unicycive Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.32
Actual
-$0.25
Surprise
+21.88%

Actinium Pharmaceuticals, Inc
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.19
Surprise
+23.45%

Marker Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.11
Actual
-$0.10
Surprise
+15.97%

Scienture Holdings, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$1.60
Actual
-$3.76
Surprise
-134.79%

60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.74
Actual
-$0.75
Surprise
-0.73%
FAQ
What were Stevanato Group S.p.A.'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Stevanato Group S.p.A. reported EPS of $0.16, beating estimates by 0.76%, and revenue of $326.10M, -0.38% below expectations.
How did the market react to Stevanato Group S.p.A.'s Q3 2026 earnings?
The stock price moved down -28.57%, changed from $19.74 before the earnings release to $14.10 the day after.
When is Stevanato Group S.p.A. expected to report next?
The next earning report is scheduled for Mar 02, 2027.
What are the forecasts for Stevanato Group S.p.A.'s next earnings report?
Based on --
analysts, Stevanato Group S.p.A. is expected to report EPS of $0.20 and revenue of $381.34M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.